Clinical Trials - April 20, 2021
AlzeCure announces positive data
AlzeCure Pharma has received positive results from the phase Ib clinical study with its drug candidate ACD440 for neuropathic pain. The results demonstrate that ACD440, a TRPV1 antagonist and AlzeCure’s drug candidate for neuropathic pain within the company’s Painless platform, was able to demonstrate positive proof-of-mechanism data, showing analgesic efficacy in man, the company states […]
Clinical Trials - December 7, 2020
AlzeCure receives approval to start clinical Phase Ib trial
AlzeCure Pharma has received approval from regulatory authorities in Germany to initiate a clinical Phase Ib study with the drug candidate ACD440. ACD440 is a drug candidate for topical use, i.e as a gel or cream, within AlzeCure’s Painless platform and focused on neuropathic pain. ACD440 has previously undergone Phase I clinical trials in which […]